Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop
This article was originally published in The Pink Sheet Daily
Executive Summary
Quality-of-life metrics deserve consideration in addition to lung function in the development of aerosolized antimicrobials, researchers say.